To evaluate the effectiveness of long-acting injectable antipsychotics (LAI-a) in reducing the 90-day and annual readmission rates in schizophrenia inpatients.

We conducted a cross-sectional study and included 180 adult patients with psychotic disorders discharged from 2018 to 2019 at a state psychiatric hospital. Descriptive statistics were used to measure the differences between the readmit and nonreadmit cohorts. Logistic regression model was used to measure the odds ratio (OR) for 90-day and annual readmission and was controlled for potential readmission risk factors.

A lower proportion of patients receiving LAI-a were readmitted within 90-day (28.6%) and 1-year (32.4%) periods. Patients receiving LAI-a had lower odds of association for 90-day (OR 0.36, 95% confidence intervals [CI] 0.139-0.921) and annual (OR 0.35, 95% CI 0.131-0.954) readmissions compared to those discharged on oral antipsychotics. A higher proportion of inpatients who received fluphenazine LAI had 90-day (25%) and annual (18.2%) readmissions compared to other LAI-a.

Utilization of LAI-a in patients with psychotic disorders can decrease both 90-day and annual psychiatric readmissions by 64% to 65%. Physicians should prefer LAI-a to reduce the readmission rate and improve the quality of life, and decrease the healthcare-related financial burden.

评估长效可注射抗精神病药 (LAI-a) 在降低精神分裂症住院患者 90 天和每年再入院率方面的有效性。

我们进行了一项横断面研究，纳入了 2018 年至 2019 年在州立精神病院出院的 180 名成年精神病患者。描述性统计用于衡量再入院和非再入院队列之间的差异。Logistic 回归模型用于测量 90 天和每年再入院的比值比 (OR)，并控制潜在的再入院风险因素。

接受 LAI-a 治疗的患者在 90 天 (28.6%) 和 1 年 (32.4%) 期间内再次入院的比例较低。与口服抗精神病药物出院的患者相比，接受 LAI-a 治疗的患者在 90 天（OR 0.36，95% 置信区间 [CI] 0.139-0.921）和每年（OR 0.35，95% CI 0.131-0.954）再入院的关联几率较低. 与其他 LAI-a 相比，接受氟奋乃静 LAI 的住院患者中有更高比例的 90 天 (25%) 和年度 (18.2%) 再入院。

在精神病患者中使用 LAI-a 可将 90 天和每年的精神病再入院率降低 64% 至 65%。医生应该更喜欢 LAI-a 以降低再入院率并改善生活质量，并减轻与医疗保健相关的经济负担。